WuXiHYbrid™

Advanced Hybridoma-Monoclonal Antibody Technologies

A world-class Hybridoma Platform

WuXiHybrid™ is a world-class hybridoma platform with the most advanced, state-of-the-art technologies, enabling our clients for generating a wide variety of monoclonal antibodies to routine and challenging targets. Our cutting-edge innovations and well-experienced expert scientists have overcome key technical bottlenecks obstacles and delivered numerous high-quality therapeutic antibodies as well as key reagent antibodies to our customers all over the world.

Summarized advantages of WuXiHybrid™ platform

Potent immunization methods using various antigen formats
High efficient cell fusion with optimized electrofusion technology
High-throughput comprehensive screening strategy
Semi-solid subcloning to assure hybridoma monoclonality

In the spirit of “striving for excellence”, our scientists will continuously make full use of the advantages of WuXiHybrid™ technology platform to provide customers with the highest quality services, and continue to be the leading team in the field of hybridoma technologies.

Immunization and Fusion Features
Strategic Screening Features
Excellent Successful Records

AAALAC accredited and licensed animal facility
Transgenic mice/rats for fully human antibody generation
Multiple immunogen choices(DNA, Peptide, Protein, Cell or combinations)
Proprietary immunization protocol to increase immune responses
High fusion efficiency through electrofusion
Modified culture media for more improved hybridoma stability
Semi-solid method for subcloning

High-throughput protein-based and cell-based screening platforms.

- Binding screen by ELISA, Mirrorball and FACS
- Reporter gene assay (RGA) for functional screening

4 high-throughput flow cytometry utilizing 5 Biacore to support screen
Abundant well established functional assays

Advanced comprehensive technical capabilities achieve 100% success
Highly customization service scope and can initiate project at any stage
Expertise and excellent records in GPCR & other Difficult Targets